Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Norcantharidin alleviates cyclophosphamide-induced immunosuppression and leukopenia in mice through NF-κB pathway

Guochuan Wang¹, Xiaolu Zhou² , Mei Yang², Xiaoyu Ma³, Xin Liu¹

¹Laboratory Medicine, Guizhou Provincial People's Hospital, Guiyang, China; ²Department of Blood Transfusion, Guizhou Provincial People's Hospital, 550002, China; ³Medical College, Guizhou University, Guiyang, Guizhou Province 550025, China.

For correspondence:- Xiaolu Zhou Email: x_luzhou0427@163.com Tel:+8613885062055

Accepted: 30 January 2023 Published: 28 February 2023

Citation: Wang G, Zhou X, Yang M, Ma X, Liu X. Norcantharidin alleviates cyclophosphamide-induced immunosuppression and leukopenia in mice through NF-κB pathway. Trop J Pharm Res 2023; 22(2):297-303 doi: 10.4314/tjpr.v22i2.11

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of norcantharidin (NCTD) on cyclophosphamide (CY)-induced immunosuppression and leukopenia in mice.

Methods: Cyclophosphamide (80 mg/kg/day) was intraperitoneally administered to mice from day 1 to 3 and day 9, and from day 4 to 10, NCTD (1, 2 and 4 mg/kg) was intraperitoneally administered. The counts of white blood cells (WBC), red blood cells (RBC) and platelets (PLT) in peripheral blood were determined, followed by the evaluation of mouse spleen and thymus indices. Histopathological examination was performed using hematoxylin-eosin (H & E) staining. In addition, the serum levels of immunoglobulins and cytokines were determined using enzyme-linked immunosorbent assay (ELISA), while plenetic T lymphocyte subsets were assessed by flow cytometry. The expression levels of p65, p-p65, IκBα, and p-IκBα in spleen tissues were determined by immunoblotting.

Results: Administration of NCTD (1, 2 and 4 mg/kg) increased blood cell counts, and alleviated injuries on splenocytes and thymocytes in CY-treated mice, accompanied by decline in spleen and thymus indices. NCTD ameliorated CY-induced immunosuppression by inhibiting the cytokines but increased the immunoglobulins. CD4+ and CD8+ T lymphocyte expressions were enhanced, especially at the high dose of NCTD (4 mg/kg). Besides, NCTD at high doses (2 and 4 mg/kg) significantly activated NF-κB pathway.

Conclusion: Administration of NCTD alleviates CY-induced leukopenia and immunosuppression in mice through activation of NF-κB pathway, thus providing a lead for the potential treatment of chemotherapy-induced leukopenia and immunosuppression.

Keywords: Norcantharidin, Cyclophosphamide, Immunosuppression, Leukopenia, Nuclear factor kappa-B